News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abcellera Biologics Inc
(NQ:
ABCL
)
3.640
-0.140 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abcellera Biologics Inc
< Previous
1
2
3
4
Next >
AbCellera Reports Q1 2024 Business Results
May 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
May 01, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
April 08, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
April 03, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
March 19, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
March 11, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
March 05, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Resignation of Board Member
February 23, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
February 22, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Full Year 2023 Business Results
February 20, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
January 23, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
December 20, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
November 16, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
November 03, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2023 Business Results
November 02, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
October 31, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
October 11, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
September 27, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
September 20, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
September 13, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q2 2023 Business Results
August 03, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
July 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
July 06, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
May 29, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
May 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2023 Business Results
May 04, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
April 17, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.